RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy [Yahoo! Finance]
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc (NASDAQ: ABEO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Abeona Therapeutics Inc (NASDAQ: ABEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.